Patents
Literature
86results about "Tripeptides" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Antibody conjugates for targeting Trop-2-expressing tumors
The present invention relates to an antibody conjugate that is particularly suitable for targeting Trop-2 expressing cells, especially tumor cells. The antibody conjugate according to the invention has the structure (1), where AB is an antibody capable of targeting Trop-2 expressing tumors, L is a linker connecting Z to D, Z is a connecting group, and L 6 -GlcNAc(Fuc) w -(G) j -S-(L 7 ) w’ -, in which G is a monosaccharide, j is an integer ranging from 0 to 10, S is a sugar or a sugar derivative, GlcNAc is N-acetylglucosamine, Fuc is fucose, w is 0 or 1, w' is 0, 1, or 2, and L 7 is -N(H)C(O)CH2-, -N(H)C(O)CF2-, or -CH2-, D is exatecan, b is 0 or 1, x is 1 or 2, and y is 1, 2, 3, or 4. The present invention further relates to methods for preparing the antibody conjugates of structure (1) and applications of the antibody conjugates of structure (1).
Owner:SYNAFFIX BV
Soluble biomolecular glass and its use
The present invention provides biomolecular glass and its use. The biomolecular glass is obtained by volatilizing a solvent from a solution of biomolecular raw materials, the solution of biomolecular raw materials comprising biomolecular raw materials, a modifier, and a solvent. The biomolecular raw materials include natural amino acids, peptides, amino acid derivatives, peptide derivatives, or mixtures of two or more of the above. The soluble biomolecular glass of the present invention has excellent biocompatibility, high light transmittance, good mechanical strength, flexible processability, and biodegradability, and can be processed into implantable or non-implantable medical materials and / or devices, fillers and stent materials, electronic sensing materials and / or devices, temporary electronic materials and / or devices, etc., and can be decomposed by living organisms or nature, with decomposition products being non-contaminating.
Owner:INSTITUTE OF PROCESS ENGINEERING CHINESE ACADEMY OF SCIENCES
Methods, compositions and kits for combination therapy
To provide a method of treating an inflammatory neurological disease or condition that can result in destruction or degeneration of axons or myelin.SOLUTION: Provided is a combination comprising a) a compound of formula (I) or a pharmaceutically or veterinarily acceptable salt thereof; and b) one or more drugs selected from the group consisting of I) a compound of a particular formula or a pharmaceutically or veterinarily acceptable salt thereof; ii) a sphingosine-1-phosphate receptor inhibitor (S1PR modulator); and iii) a signal transducer and activator of transcription 3 (STAT3) inhibitor.SELECTED DRAWING: None
Owner:ACCURE THERAPEUTICS SL +1
Method for forming a porous peptide material
Tripeptides (sequence isomers of K / Y / W) and a method for using the same. The tripeptides, upon a process of evaporation-driven self-assembly, undergo two-stage phase separation to form highly porous particles upon drying. These particles readily re-dissolved upon reintroduction of water. The particles can trap molecular payloads that can be readily released in aqueous media.
Owner:RES FOUND THE CITY UNIV OF NEW YORK
Antibody-conjugated 8-sulfonyl-benzazepine compounds and their uses
PendingJP2025505638A5Antibody ingredientsImmunoglobulins against cell receptors/antigens/surface-determinants
The present invention provides immunoconjugates of formula (I) comprising an antibody linked by conjugation to one or more 8-sulfonyl-2-aminobenzazepine derivatives. The present invention also provides 8-sulfonyl-2-aminobenzazepine derivative intermediate compositions comprising reactive functional groups. Such intermediate compositions are suitable substrates for the formation of the present immunoconjugates via a linker or linking moiety. The present invention further provides methods of treating cancer using the present immunoconjugates.
Owner:BOLT BIOTHERAPEUTICS INC
Manipulated antibody compounds and their conjugates
This invention provides novel antibody compounds and methods for using them. [Solution] Manipulated antibody compounds and their conjugates are provided, which are useful as agents for cancer immunotherapy.
Owner:ELI LILLY & CO
Conjugate of antibody and functional substance or salt thereof, and antibody derivative and compound or salts thereof to be used in producing conjugate or salt thereof
The present invention provides a conjugate of an antibody and a functional substance, said conjugate having excellent desired properties, or a salt thereof. More particularly, the present invention provides a conjugate of an antibody and a functional substance, said conjugate containing a structural unit represented by formula (1) [wherein: Ig represents an immunoglobulin unit containing two heavy chains and two light chains and bonded to LA adjacent to Ig via thiol groups in the side chains of a plurality of cysteine residues in the two heavy chains and two light chains; HG represents a hydrophilic group or a monovalent group containing a hydrophilic group; CS represents a divalent group containing a cleavable moiety; ring A represents a divalent aromatic ring group which may have a substituent (wherein the divalent aromatic ring group constitutes a π-electron conjugated system together with the aforesaid cleavable moiety); V represents an oxygen atom, a sulfur atom or an amino(NH) group; LA and LB independently represent a divalent group; D represents a functional substance; and the average number n of the aforesaid bonds per immunoglobulin unit is 1.5 or more] or a salt thereof, and substances related thereto.
De novo designed macrocyclic oligoamides
Provided are 3-4 residue non-natural macrocyclic oligoamides comprising species of 3 or 4 monomer residues selected from the group consisting of monomers a, b, c, d, e, f, g, h, I, j, k, l, m, n, o, p, q, r, s, t, u, and v as defined in Table 1, and methods for designing such macrocyclic oligoamides.
Owner:UNIV OF WASHINGTON
Peptides for treatment and prevention of nonalcoholic fatty liver disease and fibrosis
The present invention relates to peptides for the treatment or prevention of nonalcoholic fatty liver disease (NAFLD), non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH), hepatic steatosis (fatty liver), liver inflammation, cirrhosis, hepatocellular carcinoma or fibrosis, especially liver fibrosis.
Owner:UNIVERSITY OF STRASBOURG +1
Macrocyclic RAS inhibitors
PendingJP2026515696AGroup 4/14 element organic compoundsIsotope introduction to heterocyclic compounds
Owner:REVOLUTION MEDICINES INC
Antibody-drug conjugates of anti-neoplastic compounds and methods of use thereof
Disclosed is an antibody-drug conjugate that binds to human oncology targets.The antibody-drug conjugate comprises an antibody or its antigen-binding fragment that is covalently linked to two anti-neoplastic drug payloads through a dual linker, where at least one of the anti-neoplastic drug payloads is a BH3 mimetic.The disclosure further relates to a method and composition for use in treating cancer by administering the antibody-drug conjugate provided herein.Also disclosed is a linker-drug conjugate that comprises at least one BH3 mimetic and a method for making it.
Owner:NOVARTIS AG +1
Compounds, linker units comprising the same, and uses thereof in treating diseases
Provided herein is a compound having the structure of formula (I),wherein X1 is an acidic β-homo-amino acid or an acidic α-methyl-amino acid; X2 is valine (V) or leucine (L); X3 is citrulline, alanine (A) or lysine (L); A1, A2 and A3 are independently nil or a polyethylene glycol (PEG) moiety comprising 1 to 24 repeats of ethylene glycol (EG) unit; and A3 is nil when X3 is not lysine. Also provided herein are linker units including the present compound of formula (I) for linking effector elements, and antibody-drug conjugates (ADCs) including the present linker units.
Owner:T-E MEDS INC
Novel adhesion molecules
PendingJP2026031536AConnective tissue peptidesArtificial cell constructsCell biologyBiological organism
To simply utilize a biocompatible material such as chitin or chitosan as a cell culture surface and to provide a fusion protein simply utilizable for purification and proliferation of an objective cell.SOLUTION: The present invention provides a fusion protein comprising a region consisting of at least one peptide capable of adhering to chitins and a region consisting of at least one peptide or protein capable of adhering to cells.SELECTED DRAWING: Figure 1
Owner:HYPERION DRUG DISCOVERY CO LTD
Pharmaceutical and nutraceutical compositions having combinations of amino acids and their use in diseases characterized by lipid accumulation in tissues - Patents.com
The present invention discloses a pharmaceutical or dietary supplement composition that contains a specific combination of compounds including histidine, serine, cysteine and carnosine.The composition is proposed as an ingredient in food and has been proven to be effective in treating diseases characterized by the accumulation of fat in tissues, such as fatty liver disease, obesity and atherosclerosis.
Owner:FUNDACIO EURECAT +2
Iodotyrosine derivatives and methods of making iodotyrosine derivatives
ActiveCN116568694BSilicon organic compoundsOrganic compound preparationChemical compoundPerylene derivatives
The present invention relates to a compound of the general formula I wherein A is selected from the group consisting of unbranched or branched alkyl groups having 1 to 12 carbon atoms, -R 1 -O-R 2 groups, -R 1 -Si(R 3 R 4 R 5 groups, -R 1 -O-Si(R 3 R 4 R 5 groups, -C(O)-O-R 9 -Si(R 3 R 4 R 5 groups, -CH(O-R 6 )(O-R 7 ) groups, -R 1 -CH(O-R 6 )(O-R 7 ) groups, -R 1 -O-C(O)-O-R 8 groups; SG is a protecting group; R 1 is a divalent hydrocarbon residue having 1 to 12 carbon atoms; R 2 is a monovalent hydrocarbon residue having 1 to 12 carbon atoms; R 3 , R 4 and R 5 are each independently a monovalent hydrocarbon residue having 1 to 12 carbon atoms; R 6 and R 7 are each independently a monovalent hydrocarbon residue having 1 to 12 carbon atoms; R 8 is a monovalent hydrocarbon residue having 1 to 12 carbon atoms; and R 9 is a divalent hydrocarbon residue having 1 to 12 carbon atoms.
Owner:ABX ADVANCED BIOCHEM COMPOUNDS GMBH
Peptides for treatment and prevention of nonalcoholic fatty liver disease and fibrosis
The present invention relates to peptides for the treatment or prevention of nonalcoholic fatty liver disease (NAFLD), non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH), hepatic steatosis (fatty liver), liver inflammation, cirrhosis, hepatocellular carcinoma or fibrosis, especially liver fibrosis.
Owner:UNIVERSITY OF STRASBOURG +1
Antibody Drug Conjugates
The present disclosure relates to antibody drug conjugates (ADCs) comprising an antibody or antigen-binding fragment thereof covalently linked to two pharma- ceutically active drugs via a dual linker. Linker-drug conjugates comprising a dual linker and a pharma- ceutically active drug are also disclosed. Such linkers are a conventional way to deliver two (e.g., two different or the same) drugs bound to a single antibody. Such linkers may be particularly useful for improving the solubility of antibody drug conjugates (ADCs) that contain one or more hydrophobic drug compounds.
Owner:NOVARTIS AG
Regioselective conjugate of functional substance and antibody or salt of said conjugate, and antibody derivative and compound for use in production of said conjugate, or salt of said antibody derivative and compound
PendingEP4410831A4Hybrid immunoglobulinsAntibody mimetics/scaffoldsAntiendomysial antibodiesChemical compound
The present invention provides a conjugate of an antibody and a functional substance excellent in desired properties while controlling a bonding ratio between the antibody and the functional substance within a specific range, or a salt thereof. More specifically, the present invention provides a regioselective conjugate of an antibody and a functional substance comprising a structural unit represented by the following Formula (I): wherein Ig represents an immunoglobulin unit comprising two heavy chains and two light chains, and is regioselectively bonded to L1 adjacent to Ig via an amino group in side chains of lysine residues in the two heavy chains, HG represents a hydrophilic group, RA represents a side chain of a valine residue, RB represents a side chain of a citrulline residue or the like, ring A represents a divalent aromatic ring group optionally having a substituent, R1 and R2 each independently represent a hydrogen atom or a monovalent group, L1 and L2 each independently represent a divalent group, D represents a functional substance, and r is 1.5 to 2.5, or a salt thereof, and substances related thereto.
Owner:AJINOMOTO CO INC
Phosphonoalanine oligopeptides and methods of making and use thereof
Disclosed herein are compositions and methods of making and use thereof. For example, disclosed herein are compounds defined by Formula I. Also disclosed herein are compounds comprising a head group and a tail group, the head group being bound to the tail group using one or more enzymes derived from Streptomyces, wherein the head group comprises a phosphonic acid, a phosphinic acid, or a derivative thereof, and the tail group comprises one or more (canonical or non-canonical) amino acids. In some examples, the compound is a Streptomyces isolate or a derivative or salt thereof. Also disclosed herein are compositions comprising any of the compounds disclosed herein. Also disclosed herein are methods of making and use of any of the compounds or compositions disclosed herein.
Owner:OHIO STATE INNOVATION FOUND
Peptide-conjugated prodrugs
ActiveUS12622975B2Organic active ingredientsAntibacterial agentsAntibiotic AgentsPharmaceutical drug
The present disclosure relates to a conjugated prodrug comprising a peptide conjugated to an antibiotic molecules via a cleavable linker and pharmaceutical compositions thereof. Also disclosed are methods of enhancing the intracellular concentration of an antibiotic agent in a bacterium and methods of treating a patient for a bacterial infection.
Owner:BRANDEIS UNIV
Composition and method for HIP1-targeting inhibitor compounds
Provided herein is an inhibitor compound targeting Hip1, with the inhibitor compound comprising a tripeptide targeting sequence that directs the compound to the active site of Hip1 and a C-terminal electrophilic warhead conjugated to the targeting sequence, the warhead configured to inactive the enzyme.
Owner:UTAH VALLEY UNIVERSITY
Ligand-drug conjugates
PendingJP2026501817ATetrapeptide ingredientsPharmaceutical non-active ingredientsDrug conjugationPharmaceutical drug
Owner:SUN PHARMA ADVANCED RESEARCH CO LTD +1
Method for Synthesizing Amide and / or Polypeptide Using Unprotected Amino Acid as Ammonia Component
PendingUS20260008808A1Carbamic acid derivatives preparationOrganic compound preparationCarboxyl radicalCarboxylic acid
The present disclosure provides a method for synthesizing an amide and / or a polypeptide using an unprotected amino acid as an ammonia component. In the method for preparing the polypeptide, an amino acid or peptide fragment with amino and carboxyl groups both unprotected is used as an ammonia component for the synthesis of a polypeptide, and after an α-acyloxyenamide derivative of a carboxylic acid forms an amide bond or peptide bond with the amino group of the unprotected amino acid or peptide fragment, the next peptide bond construction cycle can be carried out without removing the carboxyl protecting group.
Owner:GUANGZHOU MEDICAL UNIV
Iodotyrosine derivatives and methods for producing same
ActiveJP7818005B2Group 4/14 element organic compoundsCarbamic acid derivatives preparationCombinatorial chemistryOrganic chemistry
The present invention relates to compounds of general formula I TIFF2023551497000040.tif36170 A is an unbranched or branched alkyl group having 1 to 12 carbon atoms; -R 1 -OR 2 -group, -R 1 -Si(R 3 R 4 R 5 )-group, -R 1 -O-Si(R 3 R 4 R 5 )-group, -C(O)-OR 9 -Si(R 3 R 4 R 5 )-group, -CH(OR 6 )(OR 7 )-group, -R 1 -CH(OR 6 )(OR 7 )-group, -R 1 -OC(O)-OR 8 - selected from the group consisting of groups; SG is a protecting group; R 1 is a divalent hydrocarbon group having 1 to 12 carbon atoms; R 2 is a monovalent hydrocarbon group having 1 to 12 carbon atoms; R 3 , R 4 and R 5 are each independently a monovalent hydrocarbon group having 1 to 12 carbon atoms; R 6 and R 7 are each independently a monovalent hydrocarbon group having 1 to 12 carbon atoms; R 8 is a monovalent hydrocarbon group having 1 to 12 carbon atoms R 9 is a divalent hydrocarbon group having 1 to 12 carbon atoms.
Owner:エービーエックス·アドヴァンスド·バイオケミカル·コンパウンズ-ビオメディツィーニシェ·フォルシュングスレアゲンツィエン·ゲゼルシャフト·ミト·ベシュレンクテル·ハフツング
Composition having rich-taste imparting function
A technique for effectively imparting initial taste type "kokumi" to a food or drink is provided. By using a γ-glutamyl peptide, such as γ-Glu-Val-Gly, in combination with L-tartaric acid or adipic acid, initial taste type "kokumi" is imparted to a food or drink.
Owner:AJINOMOTO CO INC
Method for selecting high-affinity compounds for target molecules
Owner:KANEKA CORP
Bifunctional chimeric heterocyclic compounds targeting degradation of androgen receptor and uses thereof
The present application relates to a kind of targeted degradation androgen receptor bifunctional chimeric heterocyclic compound and its purposes, specifically provides the compound shown in formula (I), or its isotopic compound, or its optical isomer, or its tautomer, or its pharmaceutically acceptable salt, or its prodrug, or its solvate, wherein, ARB is androgen receptor recognition / binding portion, L is linking portion, U is ubiquitin protease recognition / binding portion;Three parts are connected by chemical bond.The above-mentioned compound provided by the present application can target degradation androgen receptor in prostate cancer cell, and inhibit the proliferation of prostate cancer cell, also show good metabolic stability and pharmacokinetic property.The compound of the present application has good application prospect in the preparation of androgen receptor protein degradation targeting chimera, and the preparation of the drug for treating related diseases (including prostate cancer, breast cancer, Kennedy disease) regulated by androgen receptor.
Owner:HINOVA PHARM INC
Hollow fiber
This disclosure provides extruded or spun semipermeable porous hollow fibers, comprising covalent esters, thioesters, and / or amide-crosslinked polypeptides, as well as processes for producing the same. The hollow fibers may be produced from proteins, protein extracts, and / or protein isolates derived from plants, animals, bacteria, algae, archaea, and / or fungi, and in certain embodiments are intended to be suitable for human and / or animal ingestion. In some embodiments, the hollow fibers may be designed for use in the production of cartridges compatible with existing and / or novel bioreactor platforms for housing cell cultures in the production of cultured meat.
Owner:IP VENTURES GMBH
Novel manufacturing method for antibody-immunostimulant conjugates
The purpose of the present invention is to provide: a novel stereoselective method for producing a cyclic dinucleotide derivative that can be used for an antibody-immunostimulator conjugate; and a production intermediate thereof. Another purpose is to provide a method for producing a cyclic dinucleotide-linker and antibody-immunostimulator conjugate, in which said production method is used. Provided is a method for producing a cyclic dinucleotide derivative, the method including a step for carrying out stereoselective condensation of a compound (I) with a compound (IV) by using an optically active phosphitylation agent (Rc-II) or (Sc-II).
Owner:DAIICHI SANKYO CO LTD
Novel adhesion molecules
To simply utilize a biocompatible material such as chitin or chitosan as a cell culture surface and to provide a fusion protein simply utilizable for purification and proliferation of an objective cell.SOLUTION: The present invention provides a fusion protein comprising a region consisting of at least one peptide capable of adhering to chitins and a region consisting of at least one peptide or protein capable of adhering to cells.SELECTED DRAWING: Figure 1
Owner:HYPERION DRUG DISCOVERY CO LTD